Martindale Pharma®, Burton Hospital Announces Agreement
News Jun 02, 2016
Martindale Pharma has announced that it has signed a multi-year exclusive manufacturing agreement with Burton Hospitals NHS Foundation Trust. Under the terms of the agreement, Burton Hospitals NHS Foundation Trust will supply a number of Martindale Pharma’s key specialty generic products including Bismuth Iodoform Paraffin Paste (BIPP) and Lidocaine and Phenylephrine Topical Solution, both routine treatments in Ear Nose and Throat (ENT) surgery. Financial terms were not disclosed.
Michael Clark, Chief Marketing Officer, commented: “This news follows two years of collaborative work with the Burton Hospital, one of our best performing contract manufacturing partners. We believe this new agreement demonstrates how pharmaceutical companies can support NHS manufacturing units and offer patients the best drugs currently available on the market.”
Martindale Pharma is recognised as a strategic partner to the NHS, having maintained a close partnership with NHS manufacturing units over the years, as well as supporting NHS staff with first-class training. For the past six years, Martindale Pharma has worked with the UCL School of Pharmacy and London North West Healthcare NHS Trust’s Q3P Qualified Person (QP) Training Course providing academic and practical training to NHS Qualified Person trainees: as part of the course the pharmaceutical packaging module is hosted annually at Martindale Pharma’s Romford facility.
Michael Clark added “We are very pleased to be able to share our expertise and knowledge in the manufacturing industry with trainee QPs and NHS Manufacturing units. Our expertise, combined with our modern, upgraded UK manufacturing facility not only allows us to manufacture high quality medicines efficiently, but supply these to a wide range of countries and health care systems, notably the UK where we have over 100 different products on contract to supply the UK NHS.”
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019